577 related articles for article (PubMed ID: 22301476)
1. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.
Vesikari T; Block SL; Guerra F; Lattanzi M; Holmes S; Izu A; Gaitatzis N; Hilbert AK; Groth N
Pediatr Infect Dis J; 2012 May; 31(5):494-500. PubMed ID: 22301476
[TBL] [Abstract][Full Text] [Related]
2. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity.
Reisinger KS; Block SL; Izu A; Groth N; Holmes SJ
J Infect Dis; 2009 Sep; 200(6):849-57. PubMed ID: 19673652
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.
Szymczakiewicz-Multanowska A; Groth N; Bugarini R; Lattanzi M; Casula D; Hilbert A; Tsai T; Podda A
J Infect Dis; 2009 Sep; 200(6):841-8. PubMed ID: 19673651
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
[TBL] [Abstract][Full Text] [Related]
5. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
6. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
[TBL] [Abstract][Full Text] [Related]
7. Safety assessment and immunogenicity of a cell-culture-derived influenza vaccine in adults and elderly subjects over three successive influenza seasons.
Szymczakiewicz-Multanowska A; Lattanzi M; Izu A; Casula D; Sparacio M; Kovacs C; Groth N
Hum Vaccin Immunother; 2012 May; 8(5):645-52. PubMed ID: 22418809
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injector.
Simon JK; Carter M; Pasetti MF; Sztein MB; Kotloff KL; Weniger BG; Campbell JD; Levine MM
Vaccine; 2011 Nov; 29(51):9544-50. PubMed ID: 21986218
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.
Madhi SA; Dittmer S; Kuwanda L; Venter M; Cassim H; Lazarus E; Thomas T; Liberty A; Treurnich F; Cutland CL; Weinberg A; Violari A
AIDS; 2013 Jan; 27(3):369-79. PubMed ID: 23032417
[TBL] [Abstract][Full Text] [Related]
10. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
Lopez P; Caicedo Y; Sierra A; Tilman S; Banzhoff A; Clemens R
J Infect Dis; 2011 Jun; 203(12):1719-28. PubMed ID: 21606530
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
Englund JA; Walter E; Black S; Blatter M; Nyberg J; Ruben FL; Decker MD;
Pediatr Infect Dis J; 2010 Feb; 29(2):105-10. PubMed ID: 19934787
[TBL] [Abstract][Full Text] [Related]
12. A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine.
Ambrozaitis A; Groth N; Bugarini R; Sparacio V; Podda A; Lattanzi M
Vaccine; 2009 Oct; 27(43):6022-9. PubMed ID: 19666152
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of intradermal influenza vaccine in children.
Esposito S; Daleno C; Picciolli I; Tagliaferri L; Scala A; Prunotto G; Montinaro V; Galeone C; Principi N
Vaccine; 2011 Oct; 29(44):7606-10. PubMed ID: 21855592
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults.
Block SL; Yi T; Sheldon E; Dubovsky F; Falloon J
Vaccine; 2011 Nov; 29(50):9391-7. PubMed ID: 21983154
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
Fleming DM; Crovari P; Wahn U; Klemola T; Schlesinger Y; Langussis A; Øymar K; Garcia ML; Krygier A; Costa H; Heininger U; Pregaldien JL; Cheng SM; Skinner J; Razmpour A; Saville M; Gruber WC; Forrest B;
Pediatr Infect Dis J; 2006 Oct; 25(10):860-9. PubMed ID: 17006278
[TBL] [Abstract][Full Text] [Related]
17. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
Neuzil KM; Jackson LA; Nelson J; Klimov A; Cox N; Bridges CB; Dunn J; DeStefano F; Shay D
J Infect Dis; 2006 Oct; 194(8):1032-9. PubMed ID: 16991077
[TBL] [Abstract][Full Text] [Related]
19. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
Dong PM; Li YQ; Zheng TZ; Jia YP; Li F; Han TW; Qiao RX; Zhang BH
Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul; 24(7):570-3. PubMed ID: 12975010
[TBL] [Abstract][Full Text] [Related]
20. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.
Sindoni D; La Fauci V; Squeri R; Cannavò G; Bacilieri S; Panatto D; Gasparini R; Amicizia D
J Prev Med Hyg; 2009 Jun; 50(2):121-6. PubMed ID: 20099444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
